JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

  NCT03866707

  Condition:   Childhood Cancer
  Interventions:   Other: One-time blood draw;   Other: Evaluation of CpG methylation;   Other: Metabolomic analysis
  Sponsor:   Wake Forest University Health Sciences
  Recruiting
• Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

  NCT03505736

  Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Premenopausal;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
  Interventions:   Biological: Adenosine;   Procedure: Magnetic Resonance Imaging;   Drug: Regadenoson;   Procedure: Stress Management Therapy
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Eucrisa for Atopic Dermatitis

  NCT03250663

  Condition:   Mild to Moderate Atopic Dermatitis
  Interventions:   Behavioral: Online Treatment response;   Drug: EUCRISA
  Sponsor:   Wake Forest University Health Sciences
  Recruiting
• Vitamin D Deficiency and Dysautonomia

  NCT03032328

  Conditions:   Vitamin D Deficiency;   Orthostatic Intolerance;   Nausea
  Intervention:   Dietary Supplement: vitamin D supplement
  Sponsor:   Wake Forest University Health Sciences
  Recruiting
• Volunteering as an Intervention to Reduce Depression Among Adolescents

  NCT03816215

  Conditions:   Depression;   Adolescent Behavior;   Depressive Symptoms
  Intervention:   Behavioral: Volunteer experience
  Sponsor:   Wake Forest University Health Sciences
  Recruiting
• Measuring Health Related Quality of Life in AYAs

  NCT03482778

  Conditions:   Oncology;   Quality of Life;   PROM
  Intervention:  
  Sponsors:   Wake Forest University Health Sciences;   Feinberg School of Medicine, Northwestern University
  Recruiting
• Medical Data Collection in the Formation of Precision Oncology Registry

  NCT03874065

  Condition:   Cancer
  Intervention:   Other: Medical Chart Review
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

  NCT03662074

  Conditions:   Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Gemcitabine;   Biological: Nivolumab
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns

  NCT03564795

  Condition:   Partial-thickness Burn
  Interventions:   Device: KeraStat Gel;   Device: Silver Sulfadiazine
  Sponsors:   KeraNetics, LLC;   Wake Forest University;   United States Department of Defense
  Recruiting
• Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

  NCT02699697

  Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Bone;   Pain
  Interventions:   Radiation: External Beam Radiation Therapy;   Radiation: Palliative Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• MICU Recovery Clinic

  NCT02560129

  Conditions:   Critical Illness;   Sepsis;   Respiratory Failure;   ARDS
  Intervention:   Other: Questionnaires, Physical and Cognitive Function
  Sponsor:   Wake Forest University Health Sciences
  Recruiting
• Establishment of Cell Culture Systems From Discarded Operating Room Tissue

  NCT01000077

  Condition:   Surgery
  Intervention:  
  Sponsors:   Wake Forest University Health Sciences;   United States Department of Defense
  Recruiting
• Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders

  NCT00682513

  Conditions:   Dystonia;   Parkinsonism
  Intervention:  
  Sponsors:   University of California, Davis;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

  NCT03550313

  Condition:   Pneumococcal Infections
  Interventions:   Biological: Multivalent;   Biological: Prevnar 13
  Sponsor:   Pfizer
  Recruiting
• Flourish™ Pediatric Esophageal Atresia

  NCT03615495

  Conditions:   Esophageal Atresia;   Digestive System Abnormalities;   Esophageal Disorders Congenital
  Intervention:   Device: Flourish Pediatric Esphogeal Atresia device
  Sponsor:   Cook Research Incorporated
  Recruiting
• Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

  NCT03673462

  Condition:   Healthy Volunteers (Meningococcal Infection)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

  NCT03650452

  Conditions:   Epilepsy;   Dravet Syndrome;   Lennox-Gastaut Syndrome
  Interventions:   Drug: TAK-935;   Drug: Placebo
  Sponsors:   Takeda;   Ovid Therapeutics Inc.
  Recruiting
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

  NCT03601637

  Condition:   Cystic Fibrosis
  Interventions:   Drug: LUM;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Recruiting
• Growth and Tolerance of Infants Fed Formula for 16 Weeks

  NCT03487094

  Condition:   Child Development
  Intervention:   Other: Infant formula
  Sponsor:   Nature's One
  Recruiting
• Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

  NCT03395639

  Condition:   Cardiac Disease
  Interventions:   Drug: Edoxaban;   Drug: Standard of Care (SOC)
  Sponsor:   Daiichi Sankyo, Inc.
  Recruiting
• MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

  NCT03230838

  Conditions:   Complicated Urinary Tract Infection;   Pyelonephritis
  Interventions:   Drug: Ceftolozane;   Drug: Tazobactam;   Drug: Meropenem
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

  NCT03185819

  Condition:   Depressive Disorder, Major
  Interventions:   Drug: Intranasal Placebo;   Drug: Midazolam Placebo Solution;   Drug: Midazolam;   Drug: Esketamine
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Developmental Impact of NICU Exposures (DINE)

  NCT03061890

  Condition:   Prematurity
  Intervention:  
  Sponsors:   Albert Einstein College of Medicine;   National Institutes of Health (NIH)
  Recruiting
• Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

  NCT02914314

  Condition:   Epilepsy
  Intervention:   Drug: perampanel
  Sponsor:   Eisai Inc.
  Recruiting
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• BAX 855 Previously Untreated Patient (PUP)

  NCT02615691

  Condition:   Hemophilia A
  Intervention:   Biological: PEGylated Recombinant Factor VIII
  Sponsor:   Baxalta now part of Shire
  Recruiting
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

  NCT02369653

  Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
  Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

  NCT01146990

  Condition:   Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
  Intervention:   Drug: ASQ-3, Bayley III, Neurologic exam
  Sponsors:   AMAG Pharmaceuticals, Inc.;   Registrat-Mapi
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT02819635

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
  Sponsor:   AbbVie
  Recruiting
• Reversal Dabigatran Anticoagulant Effect With Idarucizumab

  NCT02815670

  Condition:   Hemorrhage
  Intervention:   Drug: Idarucizumab
  Sponsor:   Boehringer Ingelheim
  Recruiting
• DOSE Trial of Opioid Sparing Effect

  NCT03938857

  Conditions:   Dexmedetomidine;   Mechanical Ventilation Complication;   Critically Ill
  Interventions:   Drug: Fentanyl;   Drug: Dexmedetomidine
  Sponsors:   Duke University;   National Institutes of Health (NIH);   Johns Hopkins University;   Intermountain Health Care, Inc.;   Vanderbilt University Medical Center
  Recruiting
• An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

  NCT03921528

  Conditions:   Spinal Muscular Atrophy;   Spinal Muscular Atrophy Type 3;   Spinal Muscular Atrophy Type 2;   SMA;   Neuromuscular Diseases;   Muscular Atrophy;   Atrophy;   Muscular Atrophy, Spinal;   Neuromuscular Manifestations
  Intervention:   Biological: SRK-015
  Sponsor:   Scholar Rock, Inc.
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

  NCT03126916

  Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
  Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

  NCT03057626

  Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

  NCT04052425

  Condition:   Non-segmental Vitiligo
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle
  Sponsor:   Incyte Corporation
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement

  NCT03735667

  Condition:   Aortic Stenosis
  Interventions:   Device: ACURATE neo2™ Transfemoral TAVR System;   Device: Medtronic CoreValve TAVR System;   Device: Edwards SAPIEN 3 TAVR System
  Sponsor:   Boston Scientific Corporation
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03653026

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy

  NCT03635073

  Condition:   Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Dup15q Syndrome, CDKL5 Deficiency Disorder
  Intervention:   Drug: TAK-935
  Sponsors:   Takeda;   Ovid Therapeutics Inc.
  Recruiting
• APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

  NCT03615235

  Conditions:   Kidney Diseases;   Kidney Failure;   Kidney Disease, Chronic
  Intervention:  
  Sponsors:   Wake Forest University Health Sciences;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute on Minority Health and Health Disparities (NIMHD);   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

  NCT03593395

  Condition:   Sickle Cell Disease
  Interventions:   Other: Peer Mentoring [PM];   Other: Structured Education Based Transition Program STE
  Sponsors:   Ifeyinwa (Ify) Osunkwo MD MPH;   Patient-Centered Outcomes Research Institute
  Recruiting
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045

  Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
  Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
  Sponsor:   LivaNova
  Recruiting
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

  NCT03517722

  Condition:   Lupus Erythematosus, Systemic
  Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03493685

  Condition:   Focal Segmental Glomerulosclerosis
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

  NCT03467958

  Condition:   Crohn Disease
  Intervention:   Drug: Ozanimod
  Sponsor:   Celgene
  Recruiting
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

  NCT03464097

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension

  NCT03450629

  Conditions:   Open Angle Glaucoma;   Ocular Hypertension
  Interventions:   Drug: Brimonidine Tartrate Ophthalmic Suspension;   Drug: Brimonidine Tartrate Ophthalmic Solution
  Sponsor:   Sun Pharma Advanced Research Company Limited
  Recruiting
• Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

  NCT03440385

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

  NCT03251118

  Conditions:   Inflammatory Bowel Diseases;   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

  NCT03181932

  Conditions:   MRSA;   Cystic Fibrosis
  Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
  Sponsor:   Savara Inc.
  Recruiting
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

  NCT03112603

  Condition:   Graft-versus-host Disease (GVHD)
  Interventions:   Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib;   Drug: Ibrutinib
  Sponsor:   Incyte Corporation
  Recruiting
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

  NCT02834793

  Condition:   Lennox-Gastaut Syndrome (LGS)
  Interventions:   Drug: Placebo;   Drug: Perampanel
  Sponsor:   Eisai Inc.
  Recruiting
• Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

  NCT02830477

  Condition:   Hemophilia A, Congenital
  Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
  Sponsor:   Bayer
  Recruiting
• A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

  NCT02815891

  Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

  NCT02783651

  Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
  Intervention:   Other: Other
  Sponsor:   Amgen
  Recruiting
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

  NCT02663908

  Condition:   Prostate Cancer
  Interventions:   Drug: Degarelix;   Drug: Leuprolide
  Sponsors:   Ferring Pharmaceuticals;   Memorial Sloan Kettering Cancer Center;   Duke Clinical Research Institute
  Recruiting
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431

  Condition:   Solid Tumors Harboring NTRK Fusion
  Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
  Sponsor:   Bayer
  Recruiting
• EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

  NCT02240784

  Condition:   Acute Hepatic Porphyria
  Intervention:  
  Sponsor:   Alnylam Pharmaceuticals
  Recruiting
• Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

  NCT02392078

  Conditions:   Metastatic Brain Tumor;   Primary Brain Tumor;   Epileptic/Seizure Foci
  Intervention:   Device: NeuroBlate System
  Sponsor:   Monteris Medical
  Recruiting
• Phenotype, Genotype & Biomarkers in ALS and Related Disorders

  NCT02327845

  Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Primary Lateral Sclerosis;   Hereditary Spastic Paraplegia;   Progressive Muscular Atrophy;   Multisystem Proteinopathy
  Intervention:  
  Sponsors:   University of Miami;   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Advancing Translational Science (NCATS);   St. Jude Children's Research Hospital;   ALS Association
  Recruiting
• Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

  NCT02202434

  Condition:   Aortic Stenosis
  Interventions:   Device: Lotus Valve System;   Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System;   Device: LOTUS Edge Valve System
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Longitudinal Study of the Porphyrias

  NCT01561157

  Conditions:   Acute Porphyrias;   Cutaneous Porphyrias
  Intervention:  
  Sponsor:   Icahn School of Medicine at Mount Sinai
  Recruiting
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  NCT01790152

  Conditions:   Cancer Survivor;   Hodgkin Lymphoma in Remission;   Leukemia in Remission;   Lymphoblastic Lymphoma;   Osteosarcoma;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Neoplasm
  Interventions:   Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• 28mm Ceramic-on-Ceramic Total Hip Replacement Study

  NCT01657435

  Conditions:   Non-inflammatory Degenerative Joint Disease;   Osteoarthritis;   Avascular Necrosis;   Post-traumatic Arthritis
  Intervention:   Device: Ceramax Acetabular System
  Sponsor:   DePuy Orthopaedics
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

  NCT01522183

  Condition:   Atypical Hemolytic-Uremic Syndrome
  Intervention:  
  Sponsors:   Alexion Pharmaceuticals;   Syneos Health
  Recruiting
• Nephrotic Syndrome Study Network

  NCT01209000

  Conditions:   Minimal Change Disease (MCD);   Membranous Nephropathy;   Glomerulosclerosis, Focal Segmental
  Intervention:   Procedure: Kidney Biopsy
  Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   The NephCure Foundation
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting